Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Leukemia
; 34(4): 1182-1186, 2020 04.
Article
in En
| MEDLINE
| ID: mdl-31796915
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Azacitidine
/
Myelodysplastic Syndromes
/
Drug Resistance, Neoplasm
/
Drug-Related Side Effects and Adverse Reactions
/
Interleukin-3 Receptor alpha Subunit
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2020
Type:
Article
Affiliation country:
Germany